CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...